SharpyGLP-1 Heart Muscle Loss: Do These Drugs Shrink the Heart?
Yes, GLP-1 drugs can make the heart muscle a little smaller, but so far that looks like the heart shrinking back from the strain of extra weight, not damage. A 2024 mouse study found semaglutide shrank heart cells with no drop in pumping function, and in people with heart failure, tirzepatide cut left ventricle mass by 11 grams versus placebo while heart failure events fell. Long-term effects in healthy hearts are still unknown. To protect the muscle you can control, Sharpy gives you one daily protein target and one 20-minute strength workout.
Do GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound shrink your heart? They can make the heart muscle a bit smaller. A 2024 mouse study found it with semaglutide, and a heart scan study in people found it with tirzepatide. But in the studies so far, the heart did not pump worse, and in people with heart failure, things got better. Most experts read the human results as the heart easing back from the strain of extra weight. Long-term effects are still unknown.
The topic is back in the news this week, with fresh headlines about a weight loss drug that "shrinks heart muscle." Here is what the research actually shows.
Do GLP-1 drugs shrink heart muscle? The studies side by side
| Study | Who | Drug | What happened to heart muscle | Heart function |
|---|---|---|---|---|
| Martens et al., JACC: Basic to Translational Science, 2024 | Lean and obese mice, plus human heart cells in a dish | Semaglutide, 3 weeks | Heart weight, left ventricle mass and heart cell size went down | Ejection fraction unchanged |
| SUMMIT heart MRI substudy, JACC, 2025 | 106 adults with obesity and heart failure with preserved ejection fraction (HFpEF) | Tirzepatide up to 15 mg weekly, 52 weeks | Left ventricle mass fell 11 g more than placebo; fat around the heart fell 45 mL more | Ejection fraction and cardiac output no different from placebo |
| STEP-HFpEF heart ultrasound substudy, JACC, 2024 | 491 adults with obesity and HFpEF | Semaglutide 2.4 mg weekly, 52 weeks | No significant change in left ventricle mass | Left atrium enlarged less; filling of the heart improved |
So the picture is mixed. Mice on semaglutide lost heart mass. People with heart failure on tirzepatide lost heart mass. People with heart failure on semaglutide did not lose a measurable amount.
The mouse study behind "GLP-1 shrinks heart muscle"
The headlines trace back to a short research letter from Jason Dyck's lab at the University of Alberta. The team gave semaglutide to obese mice and to lean mice for 21 days.
- Obese mice lost about 30% of their body weight. Their heart weight, left ventricle mass and heart cell size went down.
- Lean mice barely lost weight, but they lost 8.2% of their lean mass, and their hearts got smaller too.
- Human heart cells grown in a dish also got smaller after 24 hours of semaglutide.
- Pumping function (ejection fraction) did not change in either group of mice.
The lean mice are the part that worried the researchers. Their hearts were not enlarged, yet they still shrank. The authors could not find the usual signs of muscle wasting, and they did not know why it happened. They called for heart structure and function to be checked carefully in human trials.
In the university's news release, Dyck said the benefits for people who are prescribed these drugs "should likely far exceed the risks." His bigger concern was people using them without meeting the criteria.
Keep in mind: mice are not people, the doses are not the same, and 3 weeks is short.
What heart scans in people show
Two large drug trials in people with obesity and heart failure measured the heart directly.
Tirzepatide (Mounjaro, Zepbound). In the SUMMIT trial, 106 people had a heart MRI at the start and after one year. Left ventricle mass dropped 11 grams more than with placebo. The fat pad around the heart shrank by 45 mL more. The more weight a person lost, the more their heart mass dropped. Pumping strength stayed the same. The researchers think these changes may help explain why heart failure events fell in the main trial.
Semaglutide (Wegovy). In STEP-HFpEF, 491 people had a heart ultrasound at the start and after a year. Semaglutide did not significantly change left ventricle mass. It did slow the enlargement of the upper heart chamber (left atrium) and improved how the heart fills between beats.
None of these people had healthy hearts at the start, so we still cannot say what happens in a healthy heart over many years.
Is a smaller heart bad?
Not always. The heart is a muscle that adapts to its workload. Carrying extra weight, and the higher blood pressure that often comes with it, makes the heart pump harder. Over time, the wall of the main pumping chamber can thicken. That kind of growth is a strain sign, not strength.
When weight and blood pressure come down, the heart has less work to do. Some shrinking is the expected and healthy result. That is how the SUMMIT researchers read their scans, since heart mass fell along with body weight.
The honest unknown is the one the mouse study raised: could these drugs shrink a heart that did not need to shrink? No human study has answered that yet.
Does GLP-1 weaken heart muscle or cause heart failure?
The outcome trials point the other way.
| Trial | People | Drug | Result |
|---|---|---|---|
| SELECT (NEJM, 2023) | 17,604 adults with heart disease and overweight, no diabetes | Semaglutide 2.4 mg | Heart attack, stroke or heart death: 6.5% vs 8.0% on placebo (20% lower risk) |
| SUMMIT (NEJM, 2025) | 731 adults with obesity and HFpEF | Tirzepatide | Heart death or worsening heart failure: 9.9% vs 15.3% on placebo |
In SUMMIT, the drop came from fewer worsening heart failure events. Heart deaths were few in both groups (8 vs 5), too few to draw a conclusion. For a deeper look at SELECT, see GLP-1 and cardiovascular health. If you want to know whether Wegovy is approved for heart failure, see Wegovy heart failure.
GLP-1 and heart rate
GLP-1 drugs do raise resting heart rate a little. This is on the FDA labels:
| Drug | Average resting heart rate change vs placebo |
|---|---|
| Wegovy (semaglutide) | Up 1 to 4 beats per minute in adults |
| Zepbound (tirzepatide) | Up 1 to 3 beats per minute |
The Wegovy label tells prescribers to check heart rate at regular visits. If your heart feels like it is racing while you sit still, or the change does not settle, tell your prescriber. Do not stop or change your dose on your own.
Heart muscle vs the muscle you can protect
The muscle loss most people on GLP-1 drugs should focus on is skeletal muscle: your legs, hips, back and arms. When you eat much less, part of the weight you lose comes from that muscle unless you give your body a reason to keep it. Read more in sarcopenia and GLP-1.
No study has shown a way to protect heart muscle mass on these drugs. But you can protect skeletal muscle with two habits:
- Hit a daily protein target. Most people do better spreading it over 3 or 4 meals. See how much protein you need on a GLP-1.
- Lift something 2 to 3 times a week. Bodyweight squats, rows and presses count. The beginner strength program needs no gym.
This is the part Sharpy handles. It gives you one protein number for the day, one 20-minute workout and a Shape Score that shows whether you are losing fat or muscle. If you are unsure how to split your week, start with cardio vs strength on GLP-1.
When to call your doctor
Call your doctor, or emergency services if it is severe, if you notice:
- Chest pain or pressure
- A fast or pounding heartbeat at rest that does not go away
- Shortness of breath doing things that used to be easy
- New swelling in your legs or ankles
- Fainting or feeling like you might faint
If you already have a heart condition, ask your cardiologist whether you should have any heart checks while on a GLP-1.
The bottom line
GLP-1 drugs can make the heart muscle smaller. In people, that has so far looked like the heart recovering from the load of extra weight, with steady pumping and fewer heart failure events. The mouse data keep the question open for people with healthy hearts. The muscle you can protect day to day is your skeletal muscle. Sharpy keeps that simple with one protein target and one 20-minute workout a day.
Sources
- Martens et al. Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice. JACC: Basic to Translational Science, 2024
- University of Alberta: weight loss drug found to shrink heart muscle in mice and human cells (Nov 18, 2024)
- Kramer et al. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. JACC, 2025
- Solomon et al. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure. JACC, 2024
- Packer et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). NEJM, 2025
- Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023
- Wegovy prescribing information (DailyMed)
- Zepbound prescribing information (DailyMed)
Questions people ask
Do GLP-1 drugs shrink heart muscle?
They can reduce heart muscle mass. A 2024 University of Alberta study found smaller hearts and heart cells in mice given semaglutide. In people with obesity-related heart failure, tirzepatide lowered left ventricle mass by 11 grams compared with placebo over 52 weeks. In the semaglutide heart failure study, left ventricle mass did not change significantly.
Does GLP-1 heart muscle loss mean my heart is weaker?
Not in the studies so far. In the mice, ejection fraction (how well the heart pumps) stayed the same. In the human scan studies, pumping function did not get worse, and heart failure events went down with tirzepatide. Researchers still say long-term effects need more study.
Does Ozempic weaken heart muscle?
There is no human evidence that semaglutide weakens the heart. In the SELECT trial, people with heart disease and overweight who took semaglutide 2.4 mg had 20% fewer heart attacks, strokes and heart deaths than people on placebo. The mouse finding is a reason for more research, not proof of harm.
Does GLP-1 increase heart rate?
Yes, a little. The Wegovy label reports average resting heart rate increases of 1 to 4 beats per minute in adults versus placebo. The Zepbound label reports 1 to 3 beats per minute. Tell your prescriber if your heart races at rest or the increase does not settle.
Is a smaller heart a bad thing?
It depends on why. Extra body weight makes the heart work harder, and the wall of the main pumping chamber often thickens. Losing weight lowers that load, so some shrinking can be healthy. The open question, raised by the mouse study, is whether GLP-1 drugs shrink a heart that was not enlarged to begin with.
Can I prevent heart muscle loss on a GLP-1?
No study has tested ways to protect heart muscle mass on these drugs. What you can control is skeletal muscle, the muscle in your arms, legs and back, through enough protein and regular strength training. Any heart symptoms belong with your doctor.